Shares of Novavax, Inc. (NASDAQ:NVAX) ended Tuesday session in red amid volatile trading. The shares closed down -0.22 points or -2.69% at $7.96 with 5.79 million shares getting traded. Post opening the session at $8.01, the shares hit an intraday low of $7.85 and an intraday high of $8.10 and the price vacillated in this range throughout the day. The company has a market cap of $2.27 billion and the numbers of outstanding shares have been calculated to be 271.19 million shares.
Novavax, Inc. (NVAX) announced it will host its 4th annual Investor and Analyst Meeting, Tuesday, October 11, 2016 from 9:00 a.m. – 11:00 a.m. ET in New York, NY.
Senior management will conduct a series of presentations to update analysts and investors on the Company`s ongoing clinical development programs. In addition, a key opinion leader will provide a clinical perspective on respiratory syncytial virus (RSV) disease.
Novavax expects to announce data from its pivotal Phase 3 trial of the RSV F Vaccine in older adults in the third quarter of 2016.
For additional information and registration, please email firstname.lastname@example.org or call 443-213-0506.
A live webcast of the presentations can be accessed under the “Investors”/ “Events” section of the Novavax website at novavax.com. Please allow extra time prior to the webcast to visit the site and download the streaming media software required to listen to the Internet broadcast. The webcast and a replay of the presentation will also be accessible under the “Investors/Events” section of the Novavax website at novavax.com. The event will be archived on the company`s website for 90 days.
Shares of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) ended Tuesday session in red amid volatile trading. The shares closed down -0.030 points or -3.00% at $0.970 with 257,192.00 shares getting traded. Post opening the session at $0.99, the shares hit an intraday low of $0.96 and an intraday high of $1.03 and the price vacillated in this range throughout the day. The company has a market cap of $79.67 million and the numbers of outstanding shares have been calculated to be 82.87 million shares.
Catalyst Pharmaceuticals Inc (CPRX) on Sept. 02, 2016 announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for Firdapse® (amifampridine phosphate) for the treatment of myasthenia gravis.
Myasthenia Gravis caused by antibodies to the muscle-specific kinase (MuSK-MG) is a rare disease that is estimated to inflict 5-8% of all myasthenia gravis patients (equating to an estimate of approximately 4,500 patients in the United States). MuSK antibodies identify a clinically distinguishable, more severe form of MG. The disease is characterized by a predominance in females, prominent bulbar involvement, more severe clinical condition and resistance to treatment. Although many patients with MuSK-MG are presently treated with anticholinesterase inhibitors or immunosuppressants, such patients do not generally respond adequately to these treatments.
“We are pleased that the FDA has granted Orphan Drug designation to Firdapse for myasthenia gravis, as it provides Catalyst with a number of benefits through development and commercialization,” stated Patrick J. McEnany, Chief Executive Officer of Catalyst. He continued, “We are currently supporting an investigator-sponsored, randomized, double-blind, placebo controlled study evaluating Firdapse for the treatment of patients with MuSK-MG, and we anticipate the investigator reporting top-line results from this study in early 2017. If this trial is successful, and subject to the availability of funding, we hope to initiate a registration quality trial in the U.S. evaluating Firdapse for the treatment of patients with MuSK-MG.”